ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

14,42 USD
+0,84 %+0,12
28. Nov, 02:00:00 Uhr, Nasdaq
Kommentare 58
Summer.76
Summer.76, 05.12.2022 16:19 Uhr
0
...The company expects that its common stock (together with the associated preferred stock purchase rights) will cease trading on the NYSE at market close on December 15, 2022. The company expects its common stock (together with the associated preferred stock purchase rights) to commence trading on the Nasdaq on December 16, 2022, and will continue to be listed under the ticker symbol "ZYME".
Summer.76
Summer.76, 05.12.2022 16:09 Uhr
0
https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-transfer-stock-listing-nasdaq Zymeworks To Transfer Stock Listing To Nasdaq
Summer.76
Summer.76, 29.11.2022 18:20 Uhr
0
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals https://www.businesswire.com/news/home/20221129005175/en/Zymeworks-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Zanidatamab-License-Agreement-with-Jazz-Pharmaceuticals
Summer.76
Summer.76, 22.11.2022 14:40 Uhr
0
https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-participation-upcoming-investor-conference-0
Summer.76
Summer.76, 21.11.2022 15:59 Uhr
0
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) https://www.businesswire.com/news/home/20221121005239/en/Zymeworks-Announces-Abstract-For-Zanidatamab-In-Late-Line-HER2-Positive-Hormone-Receptor-Positive-HR-Metastatic-Breast-Cancer-At-The-San-Antonio-Breast-Cancer-Symposium-SABCS ...A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022. ...
Summer.76
Summer.76, 09.11.2022 5:41 Uhr
0
Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M https://seekingalpha.com/news/3904028-zymeworks-non-gaap-eps-of-0_66-beats-0_31-revenue-of-2_6m-misses-1_95m • Zymeworks press release (NYSE:ZYME): Q3 Non-GAAP EPS of -$0.66 beats by $0.31. • Revenue of $2.6M (-40.9% Y/Y) misses by $1.95M.
Summer.76
Summer.76, 09.11.2022 5:41 Uhr
0
https://biv.com/article/2022/11/zymeworks-cuts-q3-losses-us48m-bc-biotech-reincorporates-us
Summer.76
Summer.76, 09.11.2022 5:41 Uhr
0
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results https://www.businesswire.com/news/home/20221108006218/en/Zymeworks-Provides-Corporate-Update-and-Reports-Third-Quarter-2022-Financial-Results
Summer.76
Summer.76, 31.10.2022 15:46 Uhr
0
News fehlen, aber das Volumen ist ordentlich heute.
Meistdiskutiert
Thema
1 PAIN THERAPEUTICS Hauptdiskussion +4,05 %
2 ZALANDO Hauptdiskussion -1,71 %
3 HELLOFRESH SE INH O.N. Hauptdiskussion -3,18 %
4 TUI Hauptforum -0,63 %
5 Siemens Energy ±0,00 %
6 The Forum +38,40 %
7 Vulcan Energy Resources Hauptdiskussion -8,38 %
8 NEL ASA Hauptdiskussion -1,22 %
9 Canopy Hauptforum -1,02 %
10 Europlasma Hauptdiskussion +584,04 %
Alle Diskussionen
Aktien
Thema
1 PAIN THERAPEUTICS Hauptdiskussion +4,05 %
2 ZALANDO Hauptdiskussion -1,71 %
3 HELLOFRESH SE INH O.N. Hauptdiskussion -3,18 %
4 TUI Hauptforum -0,63 %
5 Siemens Energy ±0,00 %
6 The Forum +38,40 %
7 Vulcan Energy Resources Hauptdiskussion -8,38 %
8 NEL ASA Hauptdiskussion -1,22 %
9 Canopy Hauptforum -1,02 %
10 Europlasma Hauptdiskussion +584,04 %
Alle Diskussionen